After market close on Wednesday, bluebird bio Inc
BTIG Still Says Buy
Following a conference call hosted Thursday morning to discuss the results, BTIG Equity Research analyst Dana Leone published a note maintaining the earlier stated Buy rating and $83 price target on the stock, while highlighting that the dataset hints at a bluebird and Celgene Corporation
In an earlier published note, the analyst highlights the strong efficacy and low toxicity points demonstrated by the early data with no obvious patient differences when compared with competitor data.
“As a result, we do think the know-how of Celgene manufacturing combined with the lentiviral tech transfer from BLUE may be an X factor supporting initially superior results versus the competition,” said Leone.
At time of writing, bluebird shares were trading up around 18 percent at $71.16.
Image Credit: By WitcherGeralt (Own work) [CC BY-SA 3.0], via
|Nov 2016||BMO Capital||Initiates Coverage On||Market Perform|
|Oct 2016||Cantor Fitzgerald||Downgrades||Hold||Sell|
|Sep 2016||Maxim Group||Maintains||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.